Does active thyroid hormone support hepatic LDL receptor expression and cholesterol clearance?

Executive Summary

The claim that active thyroid hormone (triiodothyronine, or T3) supports hepatic LDL receptor (LDLR) expression and cholesterol clearance, and that low free T3 (FT3) can reduce LDL clearance even when TSH and free T4 (FT4) are normal, is strongly supported by biochemical evidence and is highly plausible clinically.

While large-scale clinical trials isolated solely to "euthyroid sick" or low-T3-specific cohorts are limited, the underlying molecular physiology and epidemiological data strongly validate this relationship.

---

Myological and Pathophysiological Mechanisms

• Transcriptional Regulation of LDLR: Active triiodothyronine ($T_3$) is a potent regulator of hepatic lipid metabolism. It binds to thyroid hormone receptors (TRβ) in hepatocytes, directly activating the transcription of the low-density lipoprotein receptor ($LDLR$) gene. This upregulation is largely mediated via the sterol regulatory element-binding protein-2 (SREBP-2) pathway, which increases the density of LDL receptors on the hepatocyte surface.
• Alternative Pathway (PCSK9): $T_3$ also downregulates the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9). Because PCSK9 targets LDL receptors for lysosomal degradation, a reduction in T3-mediated inhibition results in higher PCSK9 activity, leading to increased degradation of LDLRs and further impairing LDL clearance.
• Clearance Kinetics: When $T_3$ levels fall, the density of hepatic LDL receptors decreases. This directly reduces the fractional catabolic rate of LDL-C, leaving more LDL particles circulating in the bloodstream and increasing the risk of atherogenesis.

---

Clinical and Epidemiological Evidence

• Euthyroid Population Studies: Epidemiological data consistently show that even within the "normal" reference ranges for TSH and FT4, individuals at the lower end of the FT3 range exhibit higher total cholesterol, LDL-C, and apolipoprotein B (ApoB) levels.
• Non-Thyroidal Illness Syndrome (NTIS): Often referred to as "low T3 syndrome," this state is characterized by low FT3 with normal or low TSH and FT4. Clinical observations in patients with NTIS (e.g., those with chronic illness or significant caloric restriction) frequently reveal elevated LDL-C and triglyceride profiles, illustrating that an isolated low-FT3 state can impair lipid clearance despite normal upstream pituitary signals (TSH).
• Tissue-Specific Hypothyroidism: TSH and FT4 do not always reflect peripheral tissue thyroid status. Intracellular deiodinase activity (specifically DIOn1 and DIO2, which convert T4 to T3) can be impaired. In these scenarios, "normal" lab values for TSH and FT4 mask a localized, hepatic T3 deficiency, directly resulting in reduced LDLR expression.

---

Bottom Line

The claim is highly accurate and clinically significant. Active thyroid hormone ($T_3$) is a principal driver of hepatic LDL receptor expression. An isolated low free $T_3$ level—even in the presence of completely normal TSH and free $T_4$—can directly impair the liver's ability to clear LDL cholesterol from circulation, leading to or exacerbating dyslipidemia.